semaglutide atrial fibrillation A SHOCKING CASE OF SEMAGLUTIDE-INDUCED VENTRICULAR ARRHYTHMIA GLP-1 receptor agonists were developed

The eligibility criteria for most FDA-approved weight loss drugs are as follows: Body mass index (BMI) of 30 or higher (classified as obesity) Body mass index (BMI) of 27 or higher (classified as overweight) with one weight-related health condition, such as hypertension, hyperlipidemia, heart disease, and high blood cholesterol levels

The minimum effective dose for muscle preservation during weight loss is 2-3 sessions per week targeting all major muscle groups

It is often called a triple agonist because it works on the GLP-1, GIP, and glucagon receptors together

Key Leaders: Abhinav Shashank, Co-founder and CEO